Gonadorelin [Nasal Spray]

Description

What is Gonadorelin Nasal Spray?

Gonadorelin (gonadotropin-releasing hormone; GnRH; luteinizing hormone-releasing hormone; LHRH) is a synthetic decapeptide with the sequence pyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 and a C-terminal amide. The compound is bioidentical to the endogenous hypothalamic peptide that regulates reproduction across vertebrate species. The structure and biological activity of the natural gonadotropin-releasing hormone were first reported by Schally, Arimura, Matsuo, and colleagues in 1971, who isolated the polypeptide from porcine hypothalami and demonstrated that a single peptide stimulates both luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the anterior pituitary [Schally et al., 1971; PMID 4938639]. Gonadorelin is synthesized and secreted by hypothalamic GnRH neurons in a pulsatile pattern, and the frequency and amplitude of GnRH pulses are critical determinants of the differential synthesis of LH-beta versus FSH-beta subunits at the pituitary gonadotroph level.

Gonadorelin was previously approved by the United States Food and Drug Administration under two branded formulations for human use: Factrel (gonadorelin hydrochloride injection, Wyeth) for diagnostic testing of hypothalamic-pituitary-gonadal (HPG) axis function, and Lutrepulse (gonadorelin acetate, pulsatile pump delivery) for the induction of ovulation in women with hypothalamic amenorrhea. Both human-use products were subsequently withdrawn from the US market by their manufacturers for commercial reasons, not for safety or efficacy reasons. As of June 2026, no FDA-approved gonadorelin product is commercially available for human use in the United States. A veterinary formulation (Factrel injection, Zoetis, NADA 139-237, gonadorelin hydrochloride 50 mcg/mL) remains FDA-approved for cattle only. Compounded gonadorelin is available through licensed 503A compounding pharmacies by prescription, where permitted under applicable state and federal law. The research-grade nasal spray formulation supplied by RCDbio is not a pharmaceutical product, is not a compounded medication, and is not equivalent to any formerly approved Factrel or Lutrepulse formulation.

The compound has been investigated in pituitary gonadotroph cell preparations, rodent in vivo models, and in human clinical contexts for its effects on GnRH receptor-mediated gonadotropin synthesis and secretion, HPG axis regulation, pulsatile LH and FSH release, GnRH receptor desensitization and downregulation, and differential frequency-dependent regulation of LH-beta and FSH-beta gene expression. The nasal spray formulation is investigated as a delivery route in preclinical research contexts, based on evidence of olfactory bulb-mediated CNS transport for peptide compounds administered intranasally in rodent models and the established clinical use of intranasal GnRH analog delivery (e.g., nafarelin, buserelin) for reproductive indications. Intranasal delivery has been studied for its potential to bypass hepatic first-pass metabolism and provide direct access to hypothalamic and pituitary GnRH receptor targets via olfactory nerve-mediated nose-to-brain transport. The nasal mucosa’s proximity to the central nervous system via the olfactory nerve makes it a research-relevant delivery route for CNS-active research compounds.

DISCLAIMER: Gonadorelin Nasal Spray, as supplied by RCDbio, is not a dietary supplement and has not been approved by the Food and Drug Administration for human use, veterinary use, consumption, or any therapeutic application. This product is not intended for human consumption or therapeutic self-administration. It is supplied exclusively for in vitro and preclinical laboratory research purposes. All RCDbio research compounds are for laboratory and research purposes only.

Chemical Properties of Gonadorelin

Property	Details
Product Type	Synthetic Decapeptide / Gonadotropin-Releasing Hormone / GnRH Receptor Agonist / Hypothalamic Releasing Hormone
Product Name	Gonadorelin Nasal Spray
Application	Scientific / Research Use Only
CAS Number	33515-09-2 (gonadorelin free base)
Molar Mass	1182.311 g/mol (free base, C55H75N17O13)
Chemical Formula	C55H75N17O13
IUPAC Name	(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide (PubChem CID 638793)
Synonyms	Gonadorelin; GnRH; LHRH; Luteinizing Hormone-Releasing Hormone; Gonadotropin-Releasing Hormone; pyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2; Factrel (brand name — formerly FDA-approved human diagnostic injection, Wyeth; commercially withdrawn); Lutrepulse (brand name — formerly FDA-approved pulsatile pump formulation; commercially withdrawn). Research-grade nasal spray is not equivalent to any formerly approved brand formulation.
Physical Form	Lyophilized white to off-white powder (compound); supplied as aqueous nasal spray solution
Solubility	Soluble in sterile water and 0.9% saline at ≥1 mg/mL
Storage (Lyophilized)	-20°C, desiccated, protected from light
Storage (Reconstituted / Nasal Spray)	2-8°C; use within 28 days of first actuation; DO NOT FREEZE; protect from light; keep upright
PubChem CID	638793
Purity	≥98% (HPLC verified, independent third-party laboratory analysis; COA available per batch)
WADA Status	Gonadorelin is PROHIBITED under the 2026 WADA Prohibited List, Category S2.2.1 (Testosterone-stimulating peptides in males). Gonadorelin (GnRH) is explicitly named alongside its agonist analogues. This prohibition applies in and out of competition. Note: S2.2.1 is designated specifically “in males” — researchers conducting sport-adjacent studies in female subjects should verify applicable regulatory interpretation at GlobalDRO.com.

How Does Gonadorelin Work?

Gonadorelin acts by binding to and activating the GnRH receptor (GnRHR), a Gq/11-coupled G-protein-coupled receptor expressed predominantly on anterior pituitary gonadotrophs. GnRHR activation initiates a phosphoinositide signaling cascade that releases intracellular calcium and activates protein kinase C (PKC) and mitogen-activated protein kinase (MAPK) pathways, culminating in the synthesis and secretion of LH and FSH. The frequency and amplitude of GnRH pulses critically determine the differential effects on LH versus FSH synthesis: higher pulse frequencies favor LH-beta gene promoter activation, while lower pulse frequencies preferentially activate FSH-beta gene promoter expression. The following mechanistic observations are from preclinical and in vitro data only unless otherwise specified.

GnRH Receptor Identification and HPG Axis Regulation

The hypothalamic hormone responsible for regulating both LH and FSH secretion was first isolated and structurally identified by Schally, Arimura, Matsuo, and colleagues from porcine hypothalami. A single polypeptide (pyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) was demonstrated to stimulate the release of both LH and FSH from the pituitaries of several species, and the natural and synthetic materials were shown to share biological properties [Schally et al., 1971; PMID 4938639].

GnRH Receptor Signaling: Gq/PLC/IP3/Ca²⁺/PKC/MAPK Cascade

GnRH receptor activation engages a complex intracellular signaling network in pituitary gonadotrophs. GnRH actions include activation of phosphoinositide turnover (phospholipase C-mediated IP3 and diacylglycerol generation) as well as phospholipase D and phospholipase A2, mobilization and influx of Ca2+, activation of protein kinase C (PKC), and activation of mitogen-activated protein kinase (MAPK) pathways including ERK1/2. Complex crosstalk between these messenger pathways mediates the diverse actions of GnRH on both gonadotropin secretion and gonadotropin subunit gene expression [Shacham et al., 2001; PMID 11358118].

Pulse Frequency-Dependent Differential Regulation of LH-beta and FSH-beta

The pulsatile release of GnRH by the hypothalamus is required to stimulate the pituitary-gonadal axis. In L-beta T2 gonadotroph cell preparations, LH-beta gene promoter activity was stimulated to the greatest extent at higher GnRH pulse frequencies, while FSH-beta gene promoter was preferentially stimulated at lower pulse frequencies. Cell-surface GnRH receptor density was increased at higher frequencies of pulsatile GnRH and was found to be a critical mediator of this differential regulation: overexpression of GnRH receptor abrogated the frequency-dependent induction of FSH-beta gene promoter activity [Bedecarrats & Kaiser, 2003; PMID 12697686].

Pulsatile vs. Continuous Administration: Critical Pharmacological Distinction

Gonadorelin, administered in a pulsatile pattern, stimulates LH and FSH release and maintains HPG axis activation. Continuous or tonic gonadorelin exposure leads to GnRHR desensitization and downregulation, uncoupling the pituitary from hypothalamic stimulation and producing paradoxical gonadotropin suppression and hypogonadism. This is the mechanistic principle underlying the clinical use of GnRH agonist analogs (e.g., leuprolide, goserelin) for sex steroid suppression. For research applications intended to stimulate gonadotropin secretion, pulsatile delivery protocols are required; continuous nasal spray delivery will produce a qualitatively different and potentially opposite HPG axis response.

Intranasal Delivery & Pharmacokinetics

Olfactory Bulb-Mediated CNS Transport

When administered intranasally in preclinical rodent model systems, peptide compounds can access the central nervous system through the olfactory nerve (cranial nerve I) pathway. Compounds deposited on the olfactory mucosa are transported along olfactory axons through the cribriform plate to the olfactory bulb, from which access to deeper CNS structures, including the hypothalamus, has been characterized in rodent preparations. The olfactory and trigeminal nerve pathways for nose-to-brain peptide transport have been investigated in preclinical studies of peptide and protein delivery [Wong et al., 2024; PMID 38441832]. The hypothalamic localization of GnRH receptor-expressing neurons makes nose-to-brain transport a research-relevant delivery consideration for studies of central GnRH axis pharmacology. No compound-specific intranasal CNS delivery data for research-grade gonadorelin nasal spray has been published.

Class-Level Clinical Evidence: Intranasal GnRH Analog Delivery

Unlike the majority of compounds in the RCDbio nasal spray research range, the GnRH class has an established clinical record of intranasal delivery via synthetic GnRH analogs. Nafarelin acetate (Synarel) is FDA-approved for intranasal delivery in endometriosis and central precocious puberty. Buserelin and other GnRH agonist analogs are approved for intranasal delivery in multiple jurisdictions for prostate cancer, endometriosis, and other reproductive indications. These clinical formulations use modified GnRH analogs with amino acid substitutions that enhance receptor affinity and protease resistance relative to native gonadorelin. The relevance of analog intranasal delivery data to unmodified gonadorelin nasal spray is class-level, not compound-specific.

Hepatic First-Pass Metabolism Bypass

The intranasal route avoids portal circulation and hepatic first-pass metabolic processing. Gonadorelin is rapidly metabolized by proteolytic enzymes in biological fluids, with a plasma half-life of approximately 10-40 minutes following IV or SC injection. The lack of D-amino acid substitutions and the presence of Gly at position 6 (an endopeptidase cleavage site) make native gonadorelin more susceptible to proteolytic degradation than modified GnRH analogs. The pyroglutamate N-terminal residue provides some protection against aminopeptidase attack. Intranasal delivery bypasses GI proteolytic exposure but does not protect against nasal mucosal peptidase activity to the same extent as synthetic analogs. These observations do not constitute evidence of intranasal efficacy in human subjects.

Nasal Mucosal Absorption

Gonadorelin has a molar mass of 1182.311 g/mol (~1.18 kDa). This molecular weight sits at the lower bound of the 1-5 kDa range, indicating paracellular and endocytic uptake mechanisms are likely absorption pathways at the nasal mucosa. Established clinical precedent for intranasal GnRH analog delivery supports the nasal mucosa as a viable absorption surface for GnRH-class decapeptides. Specific nasal mucosal permeability coefficients for unmodified gonadorelin have not been published.

Compound-Specific Pharmacokinetics

No formal intranasal pharmacokinetic data for research-grade gonadorelin nasal spray has been published as of June 2026. The plasma half-life of gonadorelin following IV injection is approximately 10-40 minutes based on clinical pharmacodynamic data from the formerly approved Factrel diagnostic indication. This substantially shorter half-life compared to modified GnRH analogs reflects susceptibility to endopeptidase cleavage at the Gly6-Leu7 bond. Researchers should account for rapid clearance and the absence of intranasal-specific pharmacokinetic parameters when designing laboratory protocols.

Key Research Findings

Structural Identification and Functional Characterization of Gonadotropin-Releasing Hormone (Porcine Hypothalamus, In Vivo Multi-Species Preparations): A single polypeptide isolated from porcine hypothalami (pyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) stimulates the release of both LH and FSH from the pituitaries of several species; natural and synthetic materials share identical biological properties, establishing a single hormone as the regulator of both gonadotropins [Schally et al., 1971; PMID 4938639]

GnRH Receptor Signaling Cascade — Phosphoinositide Turnover, Ca²⁺ Mobilization, PKC and MAPK Activation (Review of Pituitary Gonadotroph Signaling Mechanisms): GnRH receptor activation engages phosphoinositide turnover (PLC/IP3/DAG), phospholipase D and A2 activation, Ca2+ mobilization and influx, PKC activation, and MAPK (ERK1/2) activation in pituitary gonadotrophs; complex crosstalk between these messenger pathways mediates diverse GnRH actions on both gonadotropin secretion and LH/FSH gene expression [Shacham et al., 2001; PMID 11358118]

Pulse Frequency-Dependent Differential Regulation of LH-beta and FSH-beta Gene Promoters by GnRH (L-beta T2 Gonadotroph Cell Preparation): Higher GnRH pulse frequencies preferentially activate LH-beta gene promoter activity; lower GnRH pulse frequencies preferentially activate FSH-beta gene promoter; cell-surface GnRH receptor density is a critical mediator of this frequency-dependent differential regulation; GnRHR overexpression abrogates frequency-dependent FSH-beta induction [Bedecarrats & Kaiser, 2003; PMID 12697686]

All findings listed above are from preclinical in vitro or in vivo animal model preparations. Row 1 uses porcine hypothalamic extraction and multi-species pituitary preparations. Row 2 is a review of cell-based and in vitro gonadotroph signaling data. Row 3 characterizes GnRH pulse frequency effects in L-beta T2 gonadotroph cell preparations. These observations do not constitute evidence of efficacy or safety for gonadorelin nasal spray in any organism. The former FDA approvals for Factrel and Lutrepulse were for injectable formulations and do not validate the intranasal research-grade formulation. The pulsatile vs. continuous administration distinction is critical: continuous gonadorelin delivery produces GnRH receptor desensitization and paradoxical HPG axis suppression rather than stimulation.

What are the Potential Research Applications?

In controlled laboratory environments, gonadorelin nasal spray has been investigated for the following research applications. These are observed in preclinical and in vitro contexts only and do not constitute claims of efficacy or safety in any organism.

GnRH Receptor Pharmacology and Gonadotroph Signaling Research

Gonadorelin is the reference agonist for the GnRH receptor (GnRHR). Research applications include GnRHR binding affinity and potency assays in gonadotroph cell preparations, GnRHR desensitization and internalization kinetics studies, comparative pharmacology with GnRH analog agonists (nafarelin, leuprolide, buserelin) and antagonists (cetrorelix, ganirelix) in matched cell preparations, and Gq/PLC/IP3/Ca2+/PKC/MAPK cascade characterization in pituitary model systems.

HPG Axis Regulation and Pulsatile GnRH Research

The central role of gonadorelin in HPG axis regulation supports its use as a tool compound in neuroendocrine research. Research applications include pulsatile GnRH stimulation protocol development for rodent in vivo model systems, differential LH-beta vs. FSH-beta gene expression studies at varying pulse frequencies in gonadotroph cell preparations, GnRHR receptor density and desensitization characterization, and investigation of kisspeptin-GnRH neuron circuit interactions in rodent hypothalamic preparations.

Intranasal GnRH Axis CNS Delivery Research

The established clinical record of intranasal GnRH analog delivery and the hypothalamic localization of key GnRH axis targets support investigation of intranasal gonadorelin as a CNS-targeted delivery model. Research applications include nose-to-brain transport characterization for native GnRH decapeptide versus modified analogs, hypothalamic GnRH neuron activation following intranasal delivery in rodent preparations, and comparative nasal bioavailability studies between gonadorelin and GnRH agonist analogs.

Reproductive Endocrinology and Fertility Research

Gonadorelin’s established role in reproductive function supports its use as a reference compound in fertility-relevant research model systems. Research applications include HPG axis function assay development in rodent model systems, gonadal steroidogenesis regulation studies via LH/FSH pathway stimulation, and hypothalamic amenorrhea model characterization in rodent preparations.

What are the Potential Side Effects?

Researchers in preclinical and in vitro settings have noted the following observations. Long-term safety and toxicity profiles remain incompletely characterized for the research-grade nasal spray formulation.

• GnRHR desensitization and paradoxical HPG axis suppression (class context and critical protocol warning): Continuous or non-pulsatile gonadorelin delivery produces GnRH receptor desensitization and downregulation, leading to paradoxical suppression of LH, FSH, and downstream gonadal sex steroid production rather than stimulation; researchers using gonadorelin nasal spray must design pulsatile delivery protocols to avoid inadvertent HPG axis suppression

• Hypothalamic-pituitary-gonadal axis activation (class context): Inadvertent intranasal self-exposure carries a risk of acute LH and FSH release with downstream sex steroid elevation; repeated or continuous inadvertent exposure carries a risk of paradoxical HPG axis suppression

• Nasal mucosal sensitivity (local administration context): Local application of peptide solutions at the nasal mucosa carries risks of mucosal irritation, allergic sensitization, or epistaxis; gonadorelin is a bioidentical endogenous peptide with a low immunogenic profile relative to synthetic analogs.

• Proteolytic susceptibility of native sequence (stability consideration): Native gonadorelin is more susceptible to endopeptidase degradation at the Gly6-Leu7 bond and pyroglutamate aminopeptidase attack than synthetic GnRH analogs; this affects in vitro assay stability and biological half-life in mucosal environments

• Absence of intranasal-specific safety data for research-grade formulation: No safety or tolerability data specific to the intranasal route of administration for research-grade gonadorelin has been published in the peer-reviewed literature as of June 2026

No human safety or tolerability data has been established for this research-grade gonadorelin nasal spray formulation. The formerly approved injectable Factrel and Lutrepulse formulations provide a safety context for parenteral administration only and do not extend to the intranasal research-grade formulation.

Risk & Handling

Handling Precautions

Standard laboratory PPE is required: nitrile gloves, a laboratory coat, and eye protection. The following nasal spray-specific precautions apply:

1. Do not direct the nasal spray actuator toward the face, eyes, or mucous membranes during handling, testing, or transfer. Gonadorelin is a potent GnRH receptor agonist; inadvertent intranasal self-exposure carries a risk of acute LH/FSH release and HPG axis modulation. Repeated or continuous inadvertent exposure carries a documented risk of paradoxical HPG axis suppression via GnRHR desensitization.

2. Handle the nasal spray solution in a clean laboratory environment. For aliquoting or analytical sampling, use a laminar flow cabinet.

3. The nasal spray solution is an aqueous formulation susceptible to microbial contamination if compromised. Handle under aseptic conditions. Discard if the solution appears cloudy, discolored, or shows particulate matter.

4. Avoid aerosol generation during any manipulation of the nasal spray solution.

Exposure Risks

Risk Tier: MODERATE

Gonadorelin is a bioidentical endogenous GnRH decapeptide with a well-established safety profile in parenteral clinical use. The potency of GnRHR agonism and the critical dose and pattern dependence of its HPG axis effects — stimulation at pulsatile dosing, suppression at continuous dosing — require careful handling protocols. Inadvertent intranasal self-exposure carries a documented risk of acute HPG axis activation or, with repeated exposure, paradoxical HPG suppression. No human safety or tolerability data has been established for this research-grade gonadorelin nasal spray formulation.

Storage

In-use nasal spray: Store at 2-8°C. Use within 28 days of first actuation. Protect from light. Keep upright.

DO NOT FREEZE the ready-to-use nasal spray formulation. Freezing alters pH, buffer stability, excipient integrity, and spray actuation properties. Freezing may also promote the opening of the pyroglutamate N-terminal ring structure and aggregation of the peptide.

Lyophilized bulk stock (if applicable): Store at -20°C in sealed, desiccated, light-protected containers. Avoid repeated freeze-thaw cycles.

Discard any solution that appears cloudy, discolored, or shows visible particulate matter.

FAQs

Q: How does intranasal gonadorelin access GnRH receptor targets in preclinical research models?

A: Gonadorelin has dual GnRH receptor targets — hypothalamic GnRH neurons and anterior pituitary gonadotrophs. The intranasal route bypasses hepatic first-pass metabolism and provides access to both targets via olfactory/trigeminal nerve-mediated nose-to-brain transport. The GnRH analog class has established clinical precedent for intranasal delivery via nafarelin and buserelin, supporting the nasal mucosa as a viable absorption surface for GnRH-class decapeptides [Wong et al., 2024; PMID 38441832]. No compound-specific intranasal data exists for research-grade gonadorelin. No human intranasal delivery data has been established for this formulation.

Q: What is the recommended storage and in-use shelf life for gonadorelin nasal spray?

A: Sealed product should be stored at 2-8°C, protected from light. Once first actuated, in-use shelf life is 28 days at 2-8°C. DO NOT FREEZE the ready-to-use solution; freezing may promote pyroglutamate ring opening and aggregation. Lyophilized bulk stock should be stored at -20°C in sealed, desiccated, light-protected conditions. Discard if the solution shows cloudiness, discoloration, or particulate matter.

Q: Is the gonadorelin nasal spray formulation suitable for cell culture or in vitro assay systems?

A: The formulation is prepared in isotonic saline (0.9% NaCl, pH 5.5-7.0) without preservatives. Dilution into culture medium before application is recommended to normalize pH. Gonadorelin is a potent GnRHR agonist; researchers should account for receptor desensitization kinetics in GnRHR-expressing cell preparations. Native gonadorelin is more susceptible to peptidase degradation in serum-containing media than modified GnRH analogs. Researchers are responsible for confirming compatibility with their assay system.

Q: What is the critical pharmacological distinction between pulsatile and continuous gonadorelin administration?

A: Pulsatile gonadorelin delivery (mimicking the 60-120 minute hypothalamic pulse interval) stimulates LH and FSH release and maintains HPG axis activation, with pulse frequency differentially regulating LH-beta vs. FSH-beta synthesis [Bedecarrats & Kaiser, 2003; PMID 12697686]. Continuous or non-pulsatile delivery produces GnRHR desensitization and downregulation, leading to paradoxical suppression of gonadotropins and sex steroids. Nasal spray delivery protocols must replicate pulsatile administration to achieve stimulatory HPG effects.

Q: What is the WADA status of gonadorelin?

A: Gonadorelin is prohibited under the 2026 WADA Prohibited List, Category S2.2.1 (Testosterone-stimulating peptides in males), where it is explicitly named as “gonadotrophin-releasing hormone (GnRH, gonadorelin).”  Researchers should verify the current status at GlobalDRO.com. RCDbio products are supplied for laboratory research purposes only.

Q: What is the FDA regulatory status of gonadorelin?

A: Gonadorelin was previously FDA-approved under Factrel (gonadorelin hydrochloride injection, Wyeth) for diagnostic HPG axis testing and Lutrepulse (gonadorelin acetate, pulsatile pump) for ovulation induction. Both human-use products were withdrawn from the US market by their manufacturers for commercial reasons, not for safety or efficacy reasons. As of June 2026, no FDA-approved gonadorelin product is commercially available for human use. A veterinary formulation (Factrel injection, Zoetis, NADA 139-237) remains FDA-approved for cattle only. Compounded gonadorelin is available through licensed 503A pharmacies by prescription. The research-grade nasal spray supplied by RCDbio is not a pharmaceutical product and is not equivalent to any formerly approved formulation.

Q: How does gonadorelin differ from synthetic GnRH agonist analogs such as nafarelin, leuprolide, and buserelin?

A: Gonadorelin is the unmodified native GnRH decapeptide (pyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2), identical to the endogenous hypothalamic hormone. Synthetic GnRH agonist analogs incorporate D-amino acid substitution at position 6 and/or C-terminal substitutions that substantially increase receptor affinity, resistance to endopeptidase cleavage at the Gly6-Leu7 bond, and duration of receptor activation. These modifications make synthetic analogs more potent for receptor desensitization (sex steroid suppression) and more stable in biological matrices. Gonadorelin is the appropriate reference compound for native sequence HPG axis stimulation studies and receptor pharmacology characterization using the natural ligand.

Related Research Compounds

Researchers investigating gonadorelin nasal spray may also be interested in the following compounds currently available for laboratory research at RCDbio:

Sermorelin Nasal Spray— The native GRF(1-29) GHRH-R agonist investigated in preclinical somatotroph preparations for short-duration GH-releasing activity; shares the hypothalamic releasing hormone research context with gonadorelin as a native sequence neuroendocrine peptide.

CJC-1295 With DAC Nasal Spray — A modified, long-acting GHRH analog investigated for sustained GH axis modulation; provides a modified analog comparator to the native sequence Sermorelin, paralleling the gonadorelin vs. GnRH analog relationship.

GHRP-2 Nasal Spray— A GHS-R1a agonist investigated for GH secretagogue signaling and dual hypothalamic/pituitary target engagement via intranasal delivery; relevant as a comparator hypothalamic-pituitary axis research tool.

All products listed are for laboratory and research purposes only.

References

1. Schally, A.V., Arimura, A., Kastin, A.J., Matsuo, H., Baba, Y., Redding, T.W., Nair, R.M., Debeljuk, L., & White, W.F. (1971). Gonadotropin-releasing hormone: one polypeptide regulates the secretion of luteinizing and follicle-stimulating hormones. Science, 173(4001), 1036-1038.

   https://pubmed.ncbi.nlm.nih.gov/4938639/

2. Shacham, S., Harris, D., Ben-Shlomo, H., Cohen, I., Bonfil, D., Przedecki, F., Lewy, H., Ashkenazi, I.E., Seger, R., & Naor, Z. (2001). Mechanism of GnRH receptor signaling on gonadotropin release and gene expression in pituitary gonadotrophs. Vitamins and Hormones, 63, 63-90.

   https://pubmed.ncbi.nlm.nih.gov/11358118/

3. Bedecarrats, G.Y., & Kaiser, U.B. (2003). Differential regulation of gonadotropin subunit gene promoter activity by pulsatile gonadotropin-releasing hormone (GnRH) in perifused L beta T2 cells: role of GnRH receptor concentration. Endocrinology, 144(5), 1802-1811.

   https://pubmed.ncbi.nlm.nih.gov/12697686/

4. Wong, C.Y.J., Baldelli, A., Hoyos, C.M., et al. (2024). Insulin delivery to the brain via the nasal route: unraveling the potential for Alzheimer’s Disease therapy. Drug Delivery and Translational Research, 14(7), 1776-1793.

   https://pubmed.ncbi.nlm.nih.gov/38441832/

Research Transparency Note: No peer-reviewed publications specific to intranasal delivery of research-grade gonadorelin nasal spray are available as of June 2026. Reference 1 is the founding structural characterization of GnRH from 1971 using porcine hypothalamic isolation. Reference 2 is a comprehensive signaling review using in vitro and cell-based preparations. Reference 3 characterizes GnRH pulse frequency effects in L-beta T2 gonadotroph cell preparations in vitro. Reference 4 provides class-level intranasal peptide delivery evidence. The former FDA approvals for Factrel (IV/SC) and Lutrepulse (SC pulsatile pump) are cited for regulatory context only; they do not validate the intranasal research-grade formulation. Intranasal precedent for the GnRH class exists via approved modified analogs (nafarelin, buserelin), but native gonadorelin nasal spray has not been studied in peer-reviewed publications.

Disclaimer

Gonadorelin Nasal Spray is exclusively for laboratory research purposes. RCDbio products are not intended to diagnose, prevent, treat, or cure any disease or medical condition.

The Food and Drug Administration has not evaluated the statements on our website regarding this intranasal research formulation. This product is not approved for human or veterinary use. Researchers must comply with all applicable local, state, and federal laws and regulations governing the purchase and use of research compounds. By purchasing, you agree to our Terms and Conditions. RCDbio reserves the right to refuse sales to unauthorized individuals.

ATTENTION: All RCDbio products are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. They are not intended for human consumption, veterinary use, or any other non-research application. For queries, complaints, or support, contact support@rcdbio.co